1.
Demetri GD,
Benjamin RS,
Blanke CD,
et al.
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
J Natl Compr Canc Netw 2007;5 Suppl 2:S1-29; quiz S30.
2.
DeMatteo RP,
Lewis JJ,
Leung D,
Mudan SS,
Woodruff JM,
Brennan MF.
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Ann Surg 2000;231(1):51-58.
3.
Nikfarjam M,
Kimchi E,
Shereef S,
et al.
Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
J Gastrointest Surg 2008;12(11):2023-2031.
4.
Antoch G,
Kanja J,
Bauer S,
et al.
Comparison of PET,
CT,
and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
J Nucl Med 2004;45(3):357-365.
5.
van Oosterom AT,
Judson IR,
Verweij J,
et al.
Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
Eur J Cancer 2002;38:S83-S87.
6.
Gu J,
Khong PL,
Wang S,
Chan Q,
Law W,
Zhang J.
Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT.
Mol Imaging Biol 2011;13(5):1020-1028.
7.
Ho KC,
Lin GG,
Wang JJ,
Lai CH,
Chang CJ,
Yen TC.
Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.
Eur J Nucl Med Mol I 2009;36(2):200-208.
8.
Komori T,
Narabayashi I,
Matsumura K,
et al.
2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Ann Nucl Med 2007;21(4):209-215.
9.
Takahara T,
Imai Y,
Yamashita T,
Yasuda S,
Nasu S,
Van Cauteren M.
Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing,
STIR and high resolution 3D display.
Radiat Med 2004;22(4):275-282.
10.
Lordick F,
Ott K,
Krause BDJ,
et al.
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial.
Lancet Oncol 2007;8(9):797-805.
11.
Juweid ME,
Stroobants S,
Hoekstra OS,
et al.
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma.
J Clin Oncol 2007;25(5):571-578.
12.
Wong CS,
Gong N,
Chu YC,
et al.
Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV.
Eur J Radiol 2011; doi:10.1016/j.ejrad.2011.09.003.
13.
Young H,
Baum R,
Cremerius U,
et al.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations.
European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
Eur J Cancer 1999;35(13):1773-1782.
14.
Eisenhauer E,
Therasse P,
Bogaerls J,
et al.
New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1.
Ejc Suppl 2008;6(12):13-13.
15.
Tang L,
Zhang XP,
Sun YS,
et al.
Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients.
Radiology 2011;258(3):729-738.
16.
Lichy MP,
Aschoff P,
Plathow C,
et al.
Tumor detection by diffusion-weighted MRI and ADC-Mapping - Initial clinical experiences in comparison to PET-CT.
Invest Radiol 2007;42(9):605-613.
17.
Herholz K,
Pietrzyk U,
Voges J,
et al.
Correlation of Glucose Consumption and Tumor-Cell Density in Astrocytomas - a Stereotaxic Pet Study.
J Neurosurg 1993;79(6):853-858.
18.
Herneth AM,
Guccione S,
Bednarski M.
Apparent Diffusion Coefficient: a quantitative parameter for in vivo tumor characterization.
Eur J Radiol 2003;45(3):208-213.
19.
Nakajo M,
Kajiya Y,
Kaneko T,
et al.
FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion.
Eur J Nucl Med Mol I 2010;37(11):2011-2020.
20.
Bumming P,
Andersson J,
Meis-Kindblom JM,
et al.
Neoadjuvant,
adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
Brit J Cancer 2003;89(3):460-464.
21.
Stroszczynski C,
Jost D,
Reichardt P,
et al.
Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
Eur Radiol 2005;15(12):2448-2456.
22.
Huang CF,
Chiou SY,
Wu MF,
Tu HT,
Liu WS,
Chuang JC.
Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery.
J Neurosurg 2010;113:97-104.
23.
Brepoels L,
De Saint-Hubert M,
Stroobants S,
et al.
Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [F-18]FDG PET.
Eur J Nucl Med Mol I 2010;37(9):1688-1695.